1. Management of Prostate Cancer: Global Strategies
Antonio Alcaraz 
European Urology Supplements 
Volume 5, Issue 18, Pages (November 2006)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
Prognostic value of PSA velocity (PSAV) in detecting clinically significant pCA in an early detection setting [13]. Less-aggressive pCA was defined as stage <T2b, Gleason score <7; more-aggresive pCA was defined as stage ≥T2b, Gleason score ≥7.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
Comparison of percentage of positive surgical margins (PSM), nerve-sparing procedures, and pCA stages in patients treated with RP between 1993 and 2004 (ESPRE study). n=10,553 [24].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
Five- and 10-yr survival outcomes after RP in patients with cT3a pCA (n=200) [28]. BPFS: biochemical progression-free survival; CPFS: clinical progression-free survival; CSS: cancer-specific survival; OS: overall survival. Mean follow-up=70.6 mo.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

5. Fig. 4
Comparison of external beam radiotherapy (EBRT) and RP in terms of survival and disease progression after median follow-up of 67 mo [29].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

6. Fig. 5
Long-term risk for first and second skeletal-related events (SREs) in patients with metastatic pCA treated with zoledronic acid (ZA) compared with placebo [61].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions